The Update of Treatment for Primary Intestinal Lymphangiectasia

키워드

참고문헌 (41)

1. Wyllie R, "Pediatric gastrointestinal and liver disease", pp.2011, Elsevier
2. Wilkinson P, "Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis", N Engl J Med, 273, pp.1178~1181 (1965)
3. Kwon Y, "Individual approach for treatment of primary intestinal lymphangiectasia in children : single-center experience and review of the literature", BMC Pediatr, 21, pp.21~ (2021)
4. Edward Wolfgang Lee, "Lymphangiography to Treat Postoperative Lymphatic Leakage: A Technical Review", Korean Journal of Radiology, 15(6), pp.724~732 (2014), 대한영상의학회[DOI]
5. Altın Z, "Primary intestinal lymphangiectasia and a review of the current literature", Turk J Gastroenterol, 29, pp.714~716 (2018)
6. Takeda H, "Significance of rapid turnover proteins in protein-losing gastroenteropathy", Hepatogastroenterology, 50, pp.1963~1965 (2003)
7. Bernier JJ, "Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin", Lancet, 2, pp.763~764 (1978)
8. Schmidt PN, "Characterization and quantification of plasma proteins excreted in faeces from healthy humans", Scand J Clin Lab Invest, 55, pp.35~45 (1995)
9. Braamskamp MJ, "Clinical practice. Protein-losing enteropathy in children", Eur J Pediatr, 169, pp.1179~1185 (2010)
10. Thomas DW, "Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease", Gastroenterology, 80, pp.776~782 (1981)
11. Crossland DS, "Heart failure in adult congenital heart disease : from advanced therapies to end-of-life care", Can J Cardiol, 35, pp.1723~1739 (2019)
12. Konar A, "Protein losing enteropathy as a sole manifestation of non-Hodgkin's lymphoma", Postgrad Med J, 62, pp.399~400 (1986)
13. D'amico MA, "Protein-losing enteropathy : an unusual presentation of neuroblastoma", Clin Pediatr(Phila), 42, pp.371~373 (2003)
14. Kverneland LS, "Five decades of the Fontan operation : a systematic review of international reports on outcomes after univentricular palliation", Congenit Heart Dis, 13, pp.181~193 (2018)
15. Akkelle BS, "A rare complication of giardiasis in children:protein-losing enteropathy", Pediatr Infect Dis J, 37, pp.e345~e347 (2018)
16. Blackstone MM, "The edematous toddler : a case of pediatric Ménétrier disease", Pediatr Emerg Care, 24, pp.682~684 (2008)
17. Asakura H, "Endoscopic and histopathological study on primary and secondary intestinal lymphangiectasia", Dig Dis Sci, 26, pp.312~320 (1981)
18. Rivet C, "Use of capsule endoscopy in children with primary intestinal lymphangiectasia", Gastrointest Endosc, 64, pp.649~650 (2006)
19. Chavhan GB, "MR lymphangiography in children : technique and potential applications", Radiographics, 37, pp.1775~1790 (2017)
20. Ross AC, "Modern nutrition in health and disease" (2012), Lippincott Williams & Wilkins
21. Suresh N, "Primary intestinal lymphangiectasia", Indian Pediatr, 46, pp.903~906 (2009)
22. 권이영, "Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia", Yonsei Medical Journal, 62(5), pp.470~473 (2021), 연세대학교의과대학[DOI]
23. Itkin M, "Protein-losing enteropathy in patients with congenital heart disease", J Am Coll Cardiol, 69, pp.2929~2937 (2017)
24. Chen E, "Thoracic duct embolization for chylous leaks", Semin Intervent Radiol, 28, pp.63~74 (2011)
25. Maleux G, "Percutaneous embolization of lymphatic fistulae as treatment for protein-losing enteropathy and plastic bronchitis in patients with failing Fontan circulation", Catheter Cardiovasc Interv, 94, pp.996~1002 (2019)
26. Reichlin S, "Secretion of somatostatin and its physiologic function", J Lab Clin Med, 109, pp.320~326 (1987)
27. Suehiro K, "Late-onset primary intestinal lymphangiectasia successfully managed with octreotide : a case report", Ann Vasc Dis, 5, pp.96~99 (2012)
28. Kuroiwa G, "Primary intestinal lymphangiectasia successfully treated with octreotide", J Gastroenterol, 36, pp.129~132 (2001)
29. Baluk P, "Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract", JCI Insight, 2, pp.e90103~ (2017)
30. Kirchner GI, "Clinical pharmacokinetics of everolimus", Clin Pharmacokinet, 43, pp.83~95 (2004)
31. Ingle GR, "Sirolimus : continuing the evolution of transplant immunosuppression", Ann Pharmacother, 34, pp.1044~1055 (2000)
32. McCormack FX, "Efficacy and safety of sirolimus in lymphangioleiomyomatosis", N Engl J Med, 364, pp.1595~1606 (2011)
33. Ghobrial IM, "Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia", J Clin Oncol, 28, pp.1408~1414 (2010)
34. Hollis IB, "Medication management of cardiac allograft vasculopathy after heart transplantation", Pharmacotherapy, 35, pp.489~501 (2015)
35. Ozeki M, "Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy", Pediatrics, 137, pp.e20152562~ (2016)
36. Wagner MJ, "Propranolol for the treatment of vascular sarcomas", J Exp Pharmacol, 10, pp.51~58 (2018)
37. Liviskie CJ, "Propranolol for the treatment of lymphatic malformations in a neonate-a case report and review of literature", J Pediatr Pharmacol Ther, 25, pp.155~162 (2020)
38. Poralla C, "Treatment of congenital generalized lymphangiectasia with propranolol in a preterm infant", Pediatrics, 133, pp.e439~e442 (2014)
39. Mine K, "Intestinal lymphangiectasia markedly improved with antiplasmin therapy", Gastroenterology, 96, pp.1596~1599 (1989)
40. MacLean JE, "Primary intestinal and thoracic lymphangiectasia : a response to antiplasmin therapy", Pediatrics, 109, pp.1177~1180 (2002)
41. Prasad D, "Clinical Profile, response to therapy, and outcome of children with primary intestinal lymphangiectasia", Dig Dis, 37, pp.458~466 (2019)

관련 논문AI추천